Skip to main content
UniHealth

Doctor search

Katrina Abuabara, MD

Dermatology · San Francisco

NPI 1558689216

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
12
2 carriers
Offices
2

Offices

2 locations · University of California San Francisco · 1,780 clinicians in this group

Looking this up.

Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.

Plans that list them

12 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Abuabara’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

12 of 12 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Imperial Courage Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Dynamic Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Senior Value (HMO C-SNP)Imperial Health Plan of California, Inc.ListedSep 1, 2026

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at UCSF Medical Center
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.9 (3.79 to 6.02) · 7,590 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.8 (11.3 to 14.4) · 2,019 casesWorseJan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths139.4 (110.22 to 168.58) · 452 casesBetterJul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.622BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.626BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.491BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.8 (0.7 to 1) · 2,336 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.24 (0.58 to 1.9) · 4,689 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.05 (0.89 to 1.2)No differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.9 · 89 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.5 · 85 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.1 · 132 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.6 · 454 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 618 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 380 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.7 · 5,000 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.22 (0.06 to 0.38) · 15,965 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.2 (0.05 to 0.35) · 17,859 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.85 (0 to 1.83) · 4,184 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2 (1.1 to 2.9) · 6,516 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.35 (4.49 to 10.21) · 3,989 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5 (3.22 to 6.77) · 4,087 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.95 (0.74 to 3.15) · 2,034 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.95 (0.63 to 1.28) · 15,431 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 399 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.899No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.689No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.224No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16 · 156 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20 · 564 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits60.3 · 160 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-9.7 · 550 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits44.1 · 660 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.8 · 667 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.7 (4.8 to 6.7) · 2,019 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6 · 421 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.5 · 53 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20 · 107 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.9 (11.3 to 17.1) · 3,247 casesNo differentJan 2022 – Dec 2024

What patients said (3,181 patients answered, 25% of those asked)

Patient survey stars by topic at UCSF Medical Center
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at UCSF Medical Center
Room was "always" clean71%
Nurses "always" communicated well80%
Doctors "always" communicated well80%
Staff "always" explained61%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)76%
Staff "always" explained new medications75%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully78%
Nurses "always" treated them with courtesy and respect86%
"Always" quiet at night50%
"YES", patients would definitely recommend the hospital81%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$10,651

Medicare paid this office $10,651 for 79 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Return visit (30+ min)33$3,192$78
Short return visit (20+ min)29$1,882$51
Destruction of precancer skin growth, 1 growth27$1,649$42
Destruction of skin growth, 1-14 growths14$1,169$62
New patient visit (30+ min)13$795$61
See all 7 services
Every Original Medicare service billed
Return visit (30+ min)33$3,192$78
Short return visit (20+ min)29$1,882$51
Destruction of precancer skin growth, 1 growth27$1,649$42
Destruction of skin growth, 1-14 growths14$1,169$62
New patient visit (30+ min)13$795$61
Biopsy of related skin growth, first growth11$219$20
Destruction of precancer skin growth, 2-14 growths19$142$2

Procedures Medicare counted

Procedure volume Medicare published
Removal of skin lesions79More than 74% of doctors who do this
Skin biopsy14More than 61% of doctors who do this

Who their Medicare patients are

79 Original Medicare patients in 2024. Average age 73 · Women 63% · Also on Medicaid 34% · Health risk score 1.16. Above the middle of the specialty; the typical dermatology clinician is at 1.01.

Conditions among them: High blood pressure 56% · Depression 29% · Diabetes 23% · Chronic kidney disease 22% · Coronary heart disease 19% · COPD 14% · Atrial fibrillation 14%.

The office billed $107,022, Medicare allowed $15,282 and paid $10,651; for 267 services of 14 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
202479267731.16$107,022$10,651
20232795771.60$30,658$3,495
202273229741.02$102,553$10,762
202179229721.52$96,818$10,313
202087242721.30$82,921$6,965
201988266731.15$95,083$8,626
201871188721.60$66,498$6,304
201764184721.44$63,313$6,655
201653121671.15$43,142$4,219
20154198661.41$18,510$2,761

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 2 services

Original Medicare services billed in 2023
Return visit (30+ min)11$1,140$88
Destruction of precancer skin growth, 1 growth11$565$47

2022: 7 services

Original Medicare services billed in 2022
Return visit (30+ min)27$3,161$88
Short return visit (20+ min)34$2,220$57
Destruction of precancer skin growth, 1 growth27$1,496$43
Destruction of skin growth, 1-14 growths16$1,212$61
New patient visit (30+ min)13$861$66
Biopsy of related skin growth, first growth18$420$21
Destruction of precancer skin growth, 2-14 growths11$89$2

2021: 5 services

Original Medicare services billed in 2021
Return visit (30+ min)27$2,859$87
Short return visit (20+ min)36$2,366$54
Destruction of precancer skin growth, 1 growth24$1,065$39
Biopsy of related skin growth, first growth15$346$23
Destruction of precancer skin growth, 2-14 growths19$91$2

2020: 6 services

Original Medicare services billed in 2020
Short return visit (20+ min)43$1,893$39
Destruction of precancer skin growth, 1 growth30$1,389$41
New patient visit (30+ min)21$1,244$59
Short return visit17$348$19
Biopsy of related skin growth, first growth17$336$19
Destruction of precancer skin growth, 2-14 growths20$94$1

2019: 6 services

Original Medicare services billed in 2019
Short return visit (20+ min)50$2,732$46
New patient visit (30+ min)27$1,751$65
Destruction of precancer skin growth, 1 growth30$1,324$40
Biopsy of related skin growth, first growth20$395$18
Short return visit15$307$19
Destruction of precancer skin growth, 2-14 growths17$125$2

2018: 7 services

Original Medicare services billed in 2018
Short return visit (20+ min)37$1,974$43
Destruction of skin growth, 1-14 growths11$743$62
New patient visit (30+ min)12$631$53
Destruction of precancer skin growth, 1 growth14$616$34
Biopsy of single growth of skin and/or tissue17$552$32
New patient visit (15+ min)13$540$42
Destruction of precancer skin growth, 2-14 growths11$69$2

2017: 8 services

Original Medicare services billed in 2017
Short return visit (20+ min)29$1,958$44
New patient visit (30+ min)16$925$58
Destruction of skin growth, 1-14 growths12$822$69
Destruction of precancer skin growth, 1 growth17$784$39
Biopsy of single growth of skin and/or tissue18$647$36
New patient visit (15+ min)12$497$41
Short return visit12$295$23
Destruction of precancer skin growth, 2-14 growths13$65$2

2016: 4 services

Original Medicare services billed in 2016
Short return visit (20+ min)20$1,270$44
New patient visit (30+ min)14$802$57
Biopsy of single growth of skin and/or tissue15$436$29
New patient visit (15+ min)11$363$33

2015: 3 services

Original Medicare services billed in 2015
Short return visit (20+ min)22$666$29
New patient visit (30+ min)12$643$54
Biopsy of single growth of skin and/or tissue12$408$34

Drugs they prescribed that Part D paid

$60,082

Pharmacies billed $60,082 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 175) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.

156 generic and 19 brand-name prescriptions · $60,082 in drug cost · 20 antibiotic prescriptions.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Dupixent14$47,601$3,400
Clobetasol Propionate16$1,776$111
Ketoconazole15$423$28
Triamcinolone Acetonide15$171$11
Alendronate12$35$3
See all 6 drugs
Every Part D drug this clinician prescribed
Dupixent14$47,601$3,400
Clobetasol Propionate16$1,776$111
Ketoconazole15$423$28
Triamcinolone Acetonide15$171$11
Alendronate12$35$3
Sulfamethoxazole-Trimethoprim12$13$1

Year by year

Part D prescribing by year
2024175500% (0)11%$60,082
202345220% (0)None$10,682
2022118530% (0)None$23,632
2021165570% (0)None$15,429
2020184610% (0)14%$20,051
2019110530% (0)12%$8,721
2018128490% (0)11%$36,056
201791360% (0)21%$64,845
201669390% (0)None$6,724
201552240% (0)None$6,574
201484340% (0)None$9,373
201379270% (0)None$3,350

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2022: 3 drugs

Part D drugs prescribed in 2022
Clobetasol Propionate13$998$77
Ketoconazole12$360$30
Triamcinolone Acetonide22$270$12

2021: 2 drugs

Part D drugs prescribed in 2021
Ketoconazole28$836$30
Triamcinolone Acetonide32$722$23

2020: 5 drugs

Part D drugs prescribed in 2020
Clobetasol Propionate26$3,826$147
Tacrolimus12$2,841$237
Ketoconazole26$1,035$40
Triamcinolone Acetonide21$458$22
Gabapentin13$154$12

2019: 3 drugs

Part D drugs prescribed in 2019
Clobetasol Propionate13$1,753$135
Ketoconazole13$558$43
Triamcinolone Acetonide28$336$12

2018: 2 drugs

Part D drugs prescribed in 2018
Ketoconazole28$1,091$39
Triamcinolone Acetonide18$245$14

2017: 3 drugs

Part D drugs prescribed in 2017
Clobetasol Propionate14$2,832$202
Ketoconazole17$600$35
Triamcinolone Acetonide15$374$25

2016: 2 drugs

Part D drugs prescribed in 2016
Clobetasol Propionate15$3,148$210
Triamcinolone Acetonide12$267$22

2015: 1 drug

Part D drugs prescribed in 2015
Clobetasol Propionate13$3,327$256

2014: 1 drug

Part D drugs prescribed in 2014
Ketoconazole17$301$18

2013: 3 drugs

Part D drugs prescribed in 2013
Ketoconazole20$474$24
Ammonium Lactate14$217$16
Minocycline11$106$10

Money from drug and device companies

$7,618 in 2025

Industry payments by year
202523$7,618$7,618
2024318$23,270$27,070
202322None$56

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
GenzymeNone$4,998
2 payments
  • Paid to speak or teach · 2025-03-06 · $4,256
  • Paid to speak or teach · 2025-03-06 · $742
AmgenNone$2,620
1 payment
  • Consulting · 2025-11-18 · $2,620
See all 3 published payments
Every published payment
AmgenConsulting · 2025-11-18None$2,620
GenzymePaid to speak or teach · 2025-03-06None$4,256
GenzymePaid to speak or teach · 2025-03-06None$742
See earlier years (2024, 2023)

2024: $27,070

Payments by company in 2024
GenzymeDupixent$9,382
5 payments
  • Meals for Dupixent · 2024-05-16 · $4
  • Paid to speak or teach · 2024-03-09 · $8,200
  • Travel · 2024-03-09 · $259
  • Travel · 2024-03-09 · $742
  • Travel · 2024-03-09 · $177
IncyteOpzelura$9,178
7 payments
  • Travel for Opzelura · 2024-10-04 · $299
  • Meals for Opzelura · 2024-10-04 · $8
  • Meals for Opzelura · 2024-10-04 · $11
  • Travel for Opzelura · 2024-10-04 · $307
  • Consulting for Opzelura · 2024-10-04 · $7,650
  • Meals for Opzelura · 2024-10-04 · $24
  • Travel for Opzelura · 2024-10-03 · $880
AmgenNone$8,510
6 payments
  • Consulting · 2024-09-24 · $2,620
  • Consulting · 2024-06-05 · $4,800
  • Meals · 2024-05-31 · $146
  • Travel · 2024-05-31 · $99
  • Travel · 2024-05-30 · $193
  • Travel · 2024-05-30 · $652

2023: $56

Payments by company in 2023
AbbVieRinvoq$31
1 payment
  • Meals for Rinvoq · 2023-05-01 · $31
LEO PharmaNone$25
1 payment
  • Education · 2023-11-06 · $25

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
PFIZER INC. · The Epidemiology and Burden of Inflammatory Skin Disease in Older Adults · 2021Their institution$100,000
PFIZER INC. · The Impact of Atopic Dermatitis on Caregivers · 2020Their institution$100,000
PFIZER INC. · The Epidemiology and Burden of Inflammatory Skin Disease in Older Adults · 2022Their institution$57,460
PFIZER INC. · The Impact of Atopic Dermatitis on Caregivers · 2021Their institution$34,461
PFIZER INC. · The Epidemiology and Burden of Inflammatory Skin Disease in Older Adults · 2024Their institution$17,496
PFIZER INC. · The Impact of Atopic Dermatitis on Caregivers · 2022Their institution$14,940
Regeneron Pharmaceuticals, Inc. · Dupixent Clinical Development Program · 2022This clinician$1,522
Regeneron Pharmaceuticals, Inc. · Dupixent Clinical Development Program · 2023This clinician$206

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
74.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1558689216
Licence
PA MD452542
Trained
Harvard Medical School, 2010
Gender
Female
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207N00000X (207N00000X)
Mailing address
3600 Spruce St, 2 Maloney Bldg, Philadelphia, PA, 19104
NPI first listed
2010-05-05
NPI last updated
2014-08-07

This is when the NPI record was last certified, not a medical board exam.